Get the Stockscreener App
1.50
1.01%
0.015
Zentalis Pharmaceuticals Inc stock is traded at $1.50, with a volume of 426.89K.
It is up +1.01% in the last 24 hours and down -0.66% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.485
Open:
$1.46
24h Volume:
426.89K
Relative Volume:
0.58
Market Cap:
$108.20M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3304
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-12.28%
1M Performance:
-0.66%
6M Performance:
+5.63%
1Y Performance:
-45.05%
1-Day Range:
$1.45
$1.51
1-Week Range:
$1.45
$1.815
52-Week Range:
$1.01
$4.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.50 | 107.12M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Can Zentalis Pharmaceuticals Inc. stock reach $100 price targetTrade Volume Summary & Reliable Price Breakout Alerts - newser.com
Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
What recovery options are there for Zentalis Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Technical Confirmation Alerts - newser.com
How to build a custom watchlist for Zentalis Pharmaceuticals Inc.2025 Price Targets & Verified Chart Pattern Trade Signals - newser.com
Multi asset correlation models including Zentalis Pharmaceuticals Inc.2025 Risk Factors & Intraday High Probability Alerts - newser.com
How Zentalis Pharmaceuticals Inc. stock performs in high volatility marketsStop Loss & Fast Gaining Stock Strategy Reports - newser.com
Why Zentalis Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Can Zentalis Pharmaceuticals Inc. rally from current levelsWeekly Trend Summary & Community Consensus Stock Picks - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Bull vs Bear & High Accuracy Trade Signal Alerts - newser.com
Can Zentalis Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stock2025 Key Highlights & Community Verified Trade Alerts - newser.com
Tybourne Capital Management HK Ltd. Purchases 516,666 Shares of Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):